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The objective of this paper is to understand how the public’s beliefs in ﬁve countries may change as more families have direct
experience with Alzheimer’s disease. The data are derived from a questionnaire survey conducted by telephone (landline and cell)
with 2678 randomly selected adults in France, Germany, Poland, Spain, and the United States. The paper analyzes the beliefs and
anticipated behavior of those in each country who report having had a family member with Alzheimer’s disease versus those who
do not. In one or more countries, diﬀerences were found between the two groups in their concern about getting Alzheimer’s
disease, knowledge that the disease is fatal, awareness of certain symptoms, and support for increased public spending. The results
suggest that as more people have experience with a family member who has Alzheimer’s disease, the public will generally become
more concerned about Alzheimer’s disease and more likely to recognize that Alzheimer’s disease is a fatal disease. The ﬁndings
suggest that other beliefs may only be aﬀected if there are future major educational campaigns about the disease. The publics
in individual countries, with diﬀering cultures and health systems, are likely to respond in diﬀerent ways as more families have
experience with Alzheimer’s disease.
1.Introduction
Prevalence rates for Alzheimer’s disease in Europe and the
United States are estimated as some of the highest in the
world, growing rapidly with the aging demographic shift
[1–4]. Alzheimer’s disease is one of the leading causes of
death in these countries, and the costs imposed by it are
substantialintermsofcaregivingdemands,lostproductivity,
and strains on health care systems [5]. Among scientists,
healthprofessionals,andpolicymakers,interestinthedisease
has grown in recent years due to the growing demands
for care by patients and a number of important research
ﬁndings, including the identiﬁcation of additional genetic
risk factors and the release of new diagnostic guidelines
[6, 7]. This complements other recent scientiﬁc develop-
ments in potential drug therapies, diagnostic procedures [8],
and other research on potential risk factors, such as dietary
choices, chronic disease, and medication usage [9, 10].
Single-country surveys have looked at public attitudes
andbeliefsaboutAlzheimer’sdisease[11,12].However,little
is known about how levels of awareness and beliefs vary
across Europe and the United States, with their diﬀerent
cultures and health systems. To ﬁll this information void,
Alzheimer Europe and the Harvard School of Public Health
conducted a ﬁve-country international poll to assess public
understanding about Alzheimer’s disease [13, 14]. The poll
involved random samples of the public in France, Germany,
Poland,Spain,andtheUS.Itisimportanttolookatattitudes2 International Journal of Alzheimer’s Disease
Table 1
Interview dates Total interviews Margin of error (percentage points)
France February 7–14, 2011 529 ±4.3
Germany February 7–19, 2011 499 ±4.4
Poland February 7–10, 2011 509 ±4.3
Spain February 8–13, 2011 502 ±4.4
US February 7–27, 2011 639 ±3.9
and beliefs across countries because results from a single
countrymaynotbegeneralizabletoothercountriesthathave
diﬀerent values and experiences with Alzheimer’s disease.
The multicountry poll focused primarily on eight broad
issues. These included (1) the relative public concern about
the disease when compared to other serious national health
problems, (2) the public’s willingness to see a physician to
obtain a diagnosis if they were exhibiting symptoms possibly
associated with the disease, (3) public beliefs about whether
an eﬀective treatment to slow the progression of the disease
was currently available, (4) public beliefs about whether a
reliable test was currently available that will determine if a
person who is suﬀering from some confusion and memory
loss is in the early stages of Alzheimer’s disease, (5) the
public’s interest in future early diagnostic testing for the
disease,shouldsuchatestbecomeavailable,(6)publicbeliefs
about whether Alzheimer’s disease is a fatal disease, (7) the
level of public awareness of common symptoms that were
associated with the disease, and (8) public attitudes about
government spending on Alzheimer’s research and care.
The focus of this paper is an analysis of the beliefs and
anticipated behavior of those in each country who report
that they have had a family member with Alzheimer’s disease
versus those who say they have not. If the experience of hav-
ing a family member with Alzheimer’s disease aﬀects beliefs
and behaviors, overall public attitudes and understanding
of the disease might be expected to change as the number
of people with experience grows as a result of anticipated
demographicshifts.Therefore,understandingthediﬀerences
in perspective between those who have had a family member
with the disease and those who have not is important in
predicting possible changes in public beliefs and behaviors
in each country. We present the major ﬁndings of the
ﬁve-country poll in this comparative context and suggest
implications of the possible changesin public response inthe
years ahead.
2. Methods
2.1. Source of Data. The data are derived from a February
2011 survey by Alzheimer Europe and the Harvard School of
PublicHealthwithnationallyrepresentativerandomsamples
ofadultsage18andolderinFrance,Germany,Poland,Spain,
and the United States [13].
2.2. Study Design. In each of the ﬁve countries, interviews
were conducted of both landline telephone numbers using
random-digit dialing and cell phone numbers using a list
of random cell phone numbers across the country among
adults age 18 and older. The average length of interview was
12 minutes. Table 1 shows interview dates, samples sizes, and
marginsoferroratthe95%conﬁdencelevelforeachcountry.
The ﬁeldwork was conducted for Alzheimer Europe and
theHarvardSchoolofPublicHealthbyTNS,anindependent
research company based in London, with branches in each
of the ﬁve countries surveyed. TNS is one of the largest
survey research companies internationally and also currently
conducts the Eurobarometer surveys of adults in European
Union countries for the European Commission.
The interviews were conducted in the language of each
country. In the US, interviews were conducted in both
English and Spanish.
2.3. Poststratiﬁcation Weighting. Nonresponse in telephone
surveys produces some known biases in survey-derived
estimates because participation tends to vary for diﬀerent
subgroups of the population. To compensate for these
known biases, the sample data are weighted to reﬂect the
actual composition of the adult population in the surveyed
countries, calculated on the basis of census data from each
country, according to race/ethnicity (US only), age, gender,
and region. The sample data are also weighted by telephone
status (landline, cell). Other techniques, such as callbacks
staggeredovertimesofdaysanddaysofweeksandsystematic
respondent selection within households, are used to help
ensure that the sample in each country is representative.
The data presented in this paper are weighted percent-
ages. After weighting, the sample for each country reﬂects
the demographic composition of the adult population of
that country as presented in its census. The results for each
country are generalizable to the adult population of that
country.
2.4. Statistical Analysis. Data analysis comprises descriptive
statistics to ascertain public attitudes on each of the mea-
sures. Percentages and conﬁdence intervals (at the 95%
conﬁdence level) are shown for the responses to each survey
itemofthosewhoreportthattheyhavehadafamilymember
with Alzheimer’s disease versus those who say they have not
in each country.
The survey found that the public’s reported experience
with a family member with Alzheimer’s disease varied
substantiallyacrosstheﬁvecountries.Theproportionranged
from 19% in Poland to 30% in France, 33% in Spain, 34% in
Germany, and 42% in the US.International Journal of Alzheimer’s Disease 3
Table 2 presents comparative data for those with and
without experience for the ﬁrst six issues discussed above.
Table 3 shows comparative data between these two groups
on public perceptions of common symptoms associated
with Alzheimer’s disease. Table 4 presents comparative data
between these two groups on attitudes about government
spending related to Alzheimer’s disease. We highlight only
those diﬀerences within each country that are statistically
signiﬁcant (P<0.05).
2.5. Limitations. The poll could not identify whether
national diﬀerences in the proportion of respondents report-
ingfamilyexperiencewithAlzheimer’sdiseasewererelatedto
variation in the incidence of the disease, cultural or historical
factors that might inﬂuence the use of Alzheimer’s disease as
a diagnostic term, or diﬀerences in public education about
the disease in individual countries that might play a role in
awareness of the disease.
Those with family experience with Alzheimer’s disease
may have received educational support during this experi-
ence, which may aﬀect diﬀerences in awareness between the
experienced and nonexperienced groups.
3. Results
3.1. Relative Public Concern about Alzheimer’s Disease When
Compared to Other Serious National Health Problems.
Alzheimer’s disease is ranked as a major concern in many
countries. In three of the countries, Germany, Poland, and
the US, those with personal family experience were more
likely than those without experience to choose Alzheimer’s
disease as the disease they were most afraid of getting.
Experience did not signiﬁcantly aﬀect views in France and
Spain (Table 2).
3.2. Willingness to See a Physician to Obtain a Diagnosis
If They Were Exhibiting Symptoms Possibly Associated with
the Disease. Most report that they would see a doctor for
diagnosis if they had symptoms. There were no diﬀerences
in any country in those who would seek a physician
assessment with signs of possible Alzheimer’s disease based
on experience with having a family member who had the
disease.
3.3. Beliefs about Whether an Eﬀective Treatment to Slow
the Progression of the Disease Was Currently Available. Many
believe an eﬀective treatment to slow the progression of the
disease and make symptoms less severe is currently available.
In all ﬁve countries, experience with a family member did
not lead to diﬀerent beliefs about the current availability of
an eﬀective treatment.
3.4. Beliefs about Whether a Reliable Test Was Currently
Available That Will Determine If a Person Who Is Suﬀering
fromSomeConfusionandMemoryLossIsintheEarlyStagesof
Alzheimer’s Disease. A substantial portion of the public in all
ﬁve countries believes a reliable test is available to determine
i fap e r s o ns u ﬀering from confusion and memory loss is in
the early stages of Alzheimer’s disease. Only in one country
did experience with a family member alter beliefs about the
current availability of a reliable test. Belief increased from
44% with no family experience to 56% among those with
direct experience in Spain. In all other countries, there was
no signiﬁcant diﬀerence between the two groups.
3.5. Interest in Future Early Diagnostic Testing for the Disease,
Should Such a Test Become Available. There is substantial
public interest in early diagnostic testing. There was no
diﬀerence in any country based on personal experience with
a family member in the proportion that said they were very
likely to take a diagnostic test without symptoms.
3.6. Beliefs about Whether Alzheimer Is a Fatal Disease.
Large numbers do not believe Alzheimer is a fatal disease.
Experience with a family member increased the belief that
Alzheimer was a fatal disease in three countries—France,
Poland, and Spain. It did not in Germany and the US.
3.7. Awareness of Common Symptoms That Were Associated
with Alzheimer’s Disease. There is general agreement on
some symptoms of Alzheimer’s disease, disagreement on
others. As shown in Table 3, experience with a family
member does not change perceptions of most symptoms
across countries. Experience with Alzheimer’s disease had
no impact on beliefs about three symptoms—hallucinations,
problems with pain, and diﬃculty managing and paying
bills.
In three or more countries, experience with a family
member aﬀected beliefs about confusion and disorientation,
diﬃculty managing daily tasks, and anger and violence.
In each of these cases, experience with a family member
increased the belief that these were common symptoms of
the disease. In Poland, beliefs about two other symptoms
were aﬀected by family experience with the disease. Those
who had experience with a family member were more likely
than those without experience to believe wandering and
getting lost was a common symptom. On the other hand,
those who had experience with a family member were less
likely than those without experience to believe that diﬃculty
remembering things in their life from years before was a
common symptom.
In the US, the belief that diﬃculty remembering things
in their life from the day before was a common symptom was
increased by experience with a family member.
3.8. Attitudes about Government Spending on Alzheimer’s
Research and Care. As shown in Table 4, majorities of the
public in all ﬁve countries favor increased government
spending on research on new treatments for Alzheimer’s
disease and on caring for people who have the disease.
In two countries—Germany and Poland—those who had
experiencewithafamilymemberweremorelikelythanthose
without family experience to favor increased government
spending on research on new treatments. Only in Poland,
those with family experience were also more likely to favor4 International Journal of Alzheimer’s Disease
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Table 4: Attitudes about government spending on Alzheimer’s research and care, by experience with a family member.
Attitude about spending
Country (unweighted n for total
sample; those who have had a
family member with AD; those
who have not)
Total
% (CI 95%)
Yes, have ever had
family member with
AD
% (CI 95%)
No, have not
% (CI 95%)
P value (family
member versus no
family member)
Favor increased government
spending on research on new
treatments for Alzheimer’s
disease
France (n = 529; 166; 363) 83 (79–86) 84 (78–91) 82 (77–86) 0.497
Germany (n = 499; 177; 317) 68 (63–73) 75 (68–83) 65 (59–71) 0.032
Poland (n = 509; 92; 410) 75 (70–79) 85 (76–94) 72 (67–77) 0.013
Spain (n = 502; 172; 328) 83 (79–87) 87 (81–93) 82 (77–86) 0.212
US (n = 639; 257; 379) 67 (63–71) 66 (60–73) 68 (62–73) 0.758
Favor increased government
spending on caring for people
with Alzheimer’s disease
France (n = 529; 166; 363) 85 (81–88) 83 (77–90) 85 (81–89) 0.599
Germany (n = 499; 177; 317) 69 (64–73) 73 (65–81) 67 (61–73) 0.288
Poland (n = 509; 92; 410) 71 (67–76) 86 (77–94) 68 (63–73) 0.006
Spain (n = 502; 172; 328) 79 (75–83) 82 (76–89) 77 (71–82) 0.187
US (n = 639; 257; 379) 60 (56–64) 64 (57–70) 57 (51–63) 0.129
Source: [13].
increased spending on caring for people with Alzheimer’s
disease.
4. Discussion
Obviously, many things could change in the coming years. A
single reliable test or a new, eﬀective form of treatment could
be found, or certain lifestyle changes could be scientiﬁcally
recognized as being eﬀective. But in the absence of such
developments, one would expect certain changes of attitude
and belief to occur as more people have experience with
a family member who has Alzheimer’s disease. The results
suggest that, in general, the public will become more
concerned about Alzheimer’s disease and more likely to
recognize that Alzheimer is a fatal disease, although most
beliefs about the disease are unlikely to change.
One of the rationales for this study is that the publics
in individual countries, with diﬀering cultures and health
systems, are likely to respond in diﬀerent ways as more
families have experience with Alzheimer’s disease. What do
the survey ﬁndings mean for the future in each of the ﬁve
countries?
For France, we would expect that as the number of
people who have experience with a family member who has
Alzheimer’s disease grows, changes in public attitudes and
beliefs would change in three areas. A larger proportion of
the French public would believe that Alzheimer is a fatal
disease. In addition, more would perceive anger and violence
and confusion and disorientation to be common symptoms
of the disease.
For Germany, as the proportion of those who have family
experience with Alzheimer’s disease grows, we would expect
changes in three areas. A larger proportion of the German
public would choose Alzheimer as the disease they are most
afraid of getting. In addition, more would perceive that
diﬃculty managing daily tasks is to be a common symptom
of the disease. A larger proportion would also favor increase
of government spending on new treatments for the disease.
Poland starts out as the country with the smallest
proportion of the population reporting family experience
with Alzheimer’s disease among the ﬁve countries in the
survey. As that proportion grows in the future, we would
expect changes in public attitudes and beliefs in nine areas.
A larger proportion of the Polish public would choose
Alzheimer as the disease they are most afraid of getting,
believe that Alzheimer is a fatal disease, and perceive the
following to be common symptoms of the disease: confusion
and disorientation, diﬃculty managing daily tasks, anger
and violence, and wandering and getting lost. If the pattern
persists, one would also expect a smaller proportion to
perceive diﬃculty remembering things from their life from
years before to be a common symptom. In addition, a larger
proportionwouldbeexpectedtofavorincreasedgovernment
spending on research on new treatments for Alzheimer’s
disease and on caring for people who have the disease.
For Spain, as the proportion of those who have family
experience with Alzheimer’s disease grows, we would expect
changes in public attitudes and beliefs in three areas. A
larger proportion of the Spanish public would believe that
a reliable test is available to determine if a person suﬀering
from confusion and memory loss is in the early stages ofInternational Journal of Alzheimer’s Disease 9
Alzheimer’s disease, believe that Alzheimer is a fatal disease,
and perceive anger and confusion to be a common symptom
of the disease.
The United States starts out as the country with the
largest proportion of the population reporting family expe-
rience with Alzheimer’s disease among the ﬁve countries in
the survey. As that proportion grows in the future, we would
expect changes in public attitudes and beliefs in ﬁve areas. A
larger proportion of the US public would choose Alzheimer
as the disease they are most afraid of getting and perceive the
following to be common symptoms of the disease: confusion
anddisorientation,diﬃcultymanagingdailytasks,angerand
violence, and diﬃculty remembering things in their life from
the day before.
Looking across the ﬁve countries, the growing propor-
tion of people who have family experience with Alzheimer’s
disease is likely to have its greatest impact in Poland.
Overall, however, the survey results indicate that most of the
public’s attitudes and beliefs about Alzheimer in these ﬁve
countries may not be aﬀected by wider family experience
with the disease. These ﬁndings show the importance of
major educational campaigns about Alzheimer’s disease, its
diagnosis, treatment, and symptoms. In the absence of such
educational eﬀorts, many public attitudes and beliefs are
unlikely to change signiﬁcantly in the future. In addition,
without such an educational campaign, some beliefs that are
factually incorrect are likely to remain in the public’s mind.
These ﬁndings are important to each country because
they show the possibilities of what widespread educational
campaigns could do. Improved public education may con-
tribute to a reduction of personal and social burden in
various, for example, helping people plan for the future. The
results also suggest that educational campaigns could have
ad i ﬀerent focus in each country depending on the current
level of knowledge, awareness, and beliefs.
With Alzheimer’s disease and other forms of dementia
becoming a growing global problem [15], these ﬁndings sug-
gest that conducting surveys of the public in other countries
could provide useful information for health professionals
andpolicymakersdealingwithAlzheimer’sdiseaseandother
forms of dementia in their own country in the future.
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